Please assess the completion status of the following clinical trial:

Trial Title: The Effects of RPL554 on Top of Standard COPD Reliever Medications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Provide informed consent~* Males not donating sperm and using adequate contraception or females who are surgically sterile or postmenopausal~* 12-lead ECG showing:Heart rate 45 to 90 bpm, QTcF≤450 msec, QRS ≤120 msec, PR interval ≤220 msec, no clinically significant abnormality~* Capable of complying with all study restrictions and procedures including ability to use the study nebuliser correctly.~* BMI 18 to 33 kg/m2 with a minimum weight of 45 kg.~* COPD diagnosis for at least 1 year and clinically stable COPD in previous 4 weeks~* Demonstrates reversibility to bronchodilator (two puffs of salbutamol followed by two puffs of ipratropium) via spirometry:~  * Post-bronchodilator FEV1/forced vital capacity (FVC) ratio of ≤0.70~ * Post-bronchodilator FEV1 ≥40 % and ≤80% of predicted normal~ * ≥150 mL increase from pre-bronchodilator FEV1~* Chest X-ray showing no abnormalities~* Meet the concomitant medication restrictions and be expected to do so for the rest of the study.~* Smoking history of ≥10 pack years.~* Capable of withdrawing from long acting bronchodilators throughout the study and short acting bronchodilators for 8 hours prior to study treatment.~Exclusion Criteria:~* History of life-threatening COPD including Intensive Care Unit admission and/or requiring intubation.~* COPD exacerbation requiring oral steroids in the previous 3 months~* History of one or more hospitalisations for COPD in the previous 12 months~* Respiratory tract infection (both upper and lower) treated with antibiotics in previous 12 weeks~* Evidence of cor pulmonale or clinically significant pulmonary hypertension.~* Other respiratory disorders~* Previous lung resection or lung reduction surgery.~* Oral therapies for COPD in the previous 3 months and throughout the study.~* Drug or alcohol abuse in the past 3 years~* Received an experimental drug within 3 months or five half lives, whichever is longer.~* Prior exposure to RPL554~* Patients with a history of chronic uncontrolled disease that the Investigator believes are clinically significant.~* Documented cardiovascular disease in last 3 months~* Major surgery, (requiring general anaesthesia) in the previous 6 weeks, or will not have fully recovered from surgery, or planned surgery through the end of the study.~* History of malignancy of any organ system within 5 years with the exception of localised skin cancers (basal or squamous cell)~* Clinically significant abnormal values for safety laboratory tests~* A disclosed history, or one known to the Investigator, of significant non compliance in previous investigational studies or with prescribed medications.~* Requires oxygen therapy, even on an occasional basis.~* Inability to adequately perform whole body plethysmography.~* Any other reason that the Investigator considers makes the subject unsuitable to participate.~* Patients with known hypersensitivity to atropine or its derivatives, or to ipratropium bromide, salbutamol or RPL554 or their excipients/components.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Salbutamol alone (Type: ACTIVE_COMPARATOR): 200 micrograms salbutamol, ipratropium matched placebo and RPL554 matched placebo
- Salbutamol and RPL554 (Type: EXPERIMENTAL): 200 micrograms salbutamol, ipratropium matched placebo and 6 mg RPL554
- Ipratropium (Type: ACTIVE_COMPARATOR): Salbutamol matched placebo, 40 micrograms ipratropium and RPL554 matched placebo
- Ipratropium and RPL554 (Type: EXPERIMENTAL): Salbutamol matched placebo, 40 micrograms ipratropium and 6 mg RPL554
- RPL554 (Type: EXPERIMENTAL): Salbutamol matched placebo, ipratropium matched placebo and 6 mg RPL554
- Placebo (Type: PLACEBO_COMPARATOR): Salbutamol matched placebo, ipratropium matched placebo and RPL554 matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).